Status:
COMPLETED
Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients
Lead Sponsor:
Sohag University
Conditions:
Serum
Lipoprotein(A)
Eligibility:
All Genders
18+ years
Brief Summary
This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.
Detailed Description
Aortic valve sclerosis (AVS) has a prevalence of 2% to 7% in the population above 65 years of age. In industrialized countries, aortic valve sclerosis is most frequently caused by progressive calcific...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Both sexes.
- Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.
Exclusion
- Aortic stenosis.
- Aortic prosthesis.
- Untreated hypothyroidism.
- Severe chronic kidney failure.
- Administration of anti-inflammatory or immunosuppressive drugs.
- Pregnancy.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07209631
Start Date
October 1 2024
End Date
May 1 2025
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag University
Sohag, Egypt, 82511